bococizumab: Clinical Trials

10 trials of bococizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 terminated, 1 withdrawn. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Completed 6, Terminated 3, Withdrawn 1

Follow bococizumab: new trials by email Literature Review of bococizumab trials Research Report on bococizumab

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
Bococizumab, Placebo - Primary Hyperlipidemia or Mixed Dyslipidemia
Phase 3WithdrawnPfizer2016-10-312017-12-02
Bococizumab HIV Evaluation (B-HIVE) Study
Bococizumab, Placebo - Dyslipidemia, Cardiovascular Disease
Phase 3TerminatedUniversity of California, San Francisco112016-08-012019-06-19
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo - Hyperlipidemia
Phase 3CompletedPfizer2992015-06-012017-12-19
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia
Phase 3CompletedPfizer7462014-10-282018-07-31
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
Bococizumab (PF-04950615;RN316), Atorvastatin, Placebo for Bococizumab (PF-04950615;RN316) - Hyperlipidemia
Phase 3CompletedPfizer1842014-06-012017-12-14
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia
Phase 3CompletedPfizer21392013-10-292018-07-31
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
bococizumab (PF-04950615), Placebo - Cardiovascular Disease
Phase 3TerminatedPfizer105642013-10-292019-05-01
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
bococizumab (PF-04950615), Placebo - Cardiovascular Disease
Phase 3TerminatedPfizer167842013-10-292018-07-11
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
Bococizumab (PF-04950615;RN316), Placebo - Heterozygous Familial Hypercholesterolemia
Phase 3CompletedPfizer3702013-10-232017-06-26
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Bococizumab (PF-04950615;RN316), Placebo - Hyperlipidemia
Phase 3CompletedPfizer7112013-10-012017-05-17

Conditions studied

Hyperlipidemias (7)  ·  Cardiovascular Diseases (3)  ·  Myocardial Infarction (2)  ·  Stroke (2)  ·  Dyslipidemias (1)

Sponsors

Pfizer (9)  ·  University of California, San Francisco (1)

Countries

United States (9)  ·  Canada (7)  ·  Poland (5)  ·  United Kingdom (5)  ·  Czechia (4)  ·  Finland (4)  ·  Italy (4)  ·  Netherlands (4)  ·  South Korea (4)  ·  Spain (4)  ·  Australia (3)  ·  Colombia (3)  ·  France (3)  ·  Germany (3)  ·  Hungary (3)

Top investigators

Priscilla Y Hsue, MD (1)

Results publications

PMID 28304227, PMID 29685591, PMID 35277540, PMID 37994400, PMID 37658997, PMID 28304242, PMID 29716940, PMID 31529318

NIH funding

2014 (1)